ImmunoPass , COVID-19 Neutralizing Antibody Test, NAB 900-60 — FDA record Z-0481-2022

Reported completed

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Dec 22, 2021. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product
ImmunoPass , COVID-19 Neutralizing Antibody Test, NAB 900-60
Reason
COVID test kits were offered for sale and distributed to consumers in the United States without marketing approval, clearance, or authorization from FDA.
Classification
Class I
Recalling firm
Empowered Diagnostics LLC
Quantity
2100 units
Agency-reported status
Completed
Source record identifier
Z-0481-2022

Open the official record

What the recall classes mean. Classification is an agency assessment, not individual medical advice.

Lot and product identifiers

Label fieldDetails supplied by the agency
Lot, code or applicabilityall lots

Match all identifying details in the current notice. A brand name alone is not enough.

Distribution

US Nationwide Distribution

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Report date
Feb 9, 2022
Recall initiation date
Dec 22, 2021
Center classification date
Jan 28, 2022

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

Related records